Learn More About Pritumumab CLNH5 MultiPharm


Nascent Biotech’s lead product, Pritumumab, a natural human antibody.

The United States Patent Office has issued 11 patents for Pritumumab: 4618577; 4761377; 5093261; 5155036; 5286647; 5589573; 5602027; 6051229; 6051387; 6051693; 6165467.

Pritumumab is a fully natural human IgG antibody that was derived using proprietary technology from a B-cell isolated from a tumor draining lymph node of a patient with cervical cancer.

The recognized target is ecto-domain vimentin that is expressed on the cell surface of a variety of adenocarcinomas, including brain cancers and melanoma, but not expressed by normal tissues and cells.


Nascent Biotech has been awarded 4 patents on CLNH5 from the United States Patent Office: 4618577; 6051229; 6051387; 6090924.


MultiPharm™ is a platform technology proprietary to Nascent Biotech that may have additive and synergistic effects not only for cancer therapy but also diabetes, autoimmunity, and transplantation.

MultiPharm™ uses multiple agents (antibodies and/or cytokines).

Get the Nascent Newsletter

Stay in touch with news from Nascent Biotech when you sign up for our free newsletter.

Contact Nascent

Communicate with Nascent Biotech the quick and easy way – through our contact form.